Asia
Both companies said they plan to work together in order to strengthen their competitive positions.
The compound is a fully human monoclonal antibody targeting the IL-13 receptor alpha1 subunit and is being developed for atopic dermatitis and other inflammatory diseases.
Hitachi, Ltd. has signed a contract with Himed Hospital Management Co., Ltd., located in Xuzhou City, Jiangsu Province, People’s Republic of China, on May 29 to deliver particle therapy system with capability of irradiating both proton and heavy ion.
Teijin Pharma Limited announced that it has launched Revcovi® 2.4 mg for intramuscular injection [Elapegademase], effective immediately.
Here’s a preview of just a handful of opportunities, companies and speakers and what they’re presenting.
Biopharma companies from across Europe, Asia and North America share updates on business decisions and pipeline development.
Here’s a roundup of some of the top clinical trial news from the previous week.
On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.
Singapore-based researchers have discovered a possible solution to impede the evolution of bacteria into superbugs that are resistant to drugs and therefore harder to kill.
Researchers from Singapore have designed the world’s first ‘molecular swing’ to transport electrolytes across cell membranes.
PRESS RELEASES